Porges to Bio­gen: I don’t like your neu­ro­path­ic pain drug; Ex-Mod­er­na ex­ec Bolen joins PureTech as CSO

Leerink’s Ge­of­frey Porges is pour­ing cold wa­ter over Bio­gen’s rax­a­t­rig­ine (BI­IB074), a neu­ro­path­ic pain drug it ob­tained in their $675 mil­lion deal to buy Con­ver­gence …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.